|
|
转甲状腺素蛋白淀粉样变性一例
|
Abstract:
目的：探讨转甲状腺素蛋白淀粉样变性(ATTR)的临床诊断、治疗及预后。方法：回顾性分析安徽医科大学第一附属医院2022年收治的1例ATTR患者的临床资料，并进行相关文献复习。结果：患者，男性，43岁，初期表现为间断腹泻，随后因双下肢麻木乏力行神经活检提示神经淀粉样变性，现因双下肢浮肿及尿失禁就诊，经综合检查考虑淀粉样变性多系统累及，完善心脏磁共振、99mTc-PYP核素显像及基因检测，确诊ATTR，现予以氯苯唑酸治疗，随访截至2024年12月，患者病情稳定。结论：ATTR为淀粉样变性中的罕见类型，病例少，病情进展快，临床表现缺乏特异性，虽有针对性的治疗药物，但需做到早期诊断及治疗，总体预后不佳。
Abstract: To explore the clinical diagnosis, treatment, and prognosis of transthyretin amyloidosis (ATTR). Method: A retrospective analysis was conducted on the clinical data of a patient with ATTR admitted to the First Affiliated Hospital of Anhui Medical University in 2022, and relevant literature was reviewed. Result: The patient, a 43-year-old male, initially presented with intermittent diarrhea. Subsequently, nerve biopsy was performed due to numbness and weakness in both lower limbs, indicating neuroamyloidosis. The patient is now seeking medical attention due to edema and urinary incontinence in both lower limbs. After comprehensive examination, it was considered that amyloidosis involves multiple systems. After completing cardiac magnetic resonance imaging, 99mTc PYP nuclear imaging, and genetic testing, the patient was diagnosed with ATTR and is now receiving treatment with chlorpromazine. Follow-up until December 2024 shows that the patient’s condition is stable. Conclusion: ATTR is a rare type of amyloidosis with few cases, rapid disease progression, and lack of specificity in clinical manifestations. Although there are targeted therapeutic drugs, early diagnosis and treatment are necessary, and the overall prognosis is poor.
| [1] | Gillmore, J.D. and Hawkins, P.N. (2013) Pathophysiology and Treatment of Systemic Amyloidosis. Nature Reviews Nephrology, 9, 574-586. https://doi.org/10.1038/nrneph.2013.171 |
| [2] | Donnelly, J.P. and Hanna, M. (2017) Cardiac Amyloidosis: An Update on Diagnosis and Treatment. Cleveland Clinic Journal of Medicine, 84, 12-26. https://doi.org/10.3949/ccjm.84.s3.02 |
| [3] | Sipe, J.D., Benson, M.D., Buxbaum, J.N., Ikeda, S., Merlini, G., Saraiva, M.J.M., et al. (2016) Amyloid Fibril Proteins and Amyloidosis: Chemical Identification and Clinical Classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid, 23, 209-213. https://doi.org/10.1080/13506129.2016.1257986 |
| [4] | Sekijima, Y., Kelly, J. and Ikeda, S. (2008) Pathogenesis of and Therapeutic Strategies to Ameliorate the Transthyretin Amyloidoses. Current Pharmaceutical Design, 14, 3219-3230. https://doi.org/10.2174/138161208786404155 |
| [5] | Liz, M.A., Mar, F.M., Franquinho, F. and Sousa, M.M. (2010) Aboard Transthyretin: From Transport to Cleavage. IUBMB Life, 62, 429-435. https://doi.org/10.1002/iub.340 |
| [6] | Merlini, G. and Bellotti, V. (2003) Molecular Mechanisms of Amyloidosis. New England Journal of Medicine, 349, 583-596. https://doi.org/10.1056/nejmra023144 |
| [7] | Ruberg, F.L. and Berk, J.L. (2012) Transthyretin (TTR) Cardiac Amyloidosis. Circulation, 126, 1286-1300. https://doi.org/10.1161/circulationaha.111.078915 |
| [8] | Conceição, I., Damy, T., Romero, M., Galán, L., Attarian, S., Luigetti, M., et al. (2019) Early Diagnosis of ATTR Amyloidosis through Targeted Follow-Up of Identified Carriers of TTR Gene Mutations. Amyloid, 26, 3-9. https://doi.org/10.1080/13506129.2018.1556156 |
| [9] | Coelho, T., Maurer, M.S. and Suhr, O.B. (2012) THAOS—The Transthyretin Amyloidosis Outcomes Survey: Initial Report on Clinical Manifestations in Patients with Hereditary and Wild-Type Transthyretin Amyloidosis. Current Medical Research and Opinion, 29, 63-76. https://doi.org/10.1185/03007995.2012.754348 |
| [10] | Jacobson, D., McFarlin, D., Kane, I. and Buxbaum, J. (1992) Transthyretin Pro55, a Variant Associated with Early-Onset, Aggressive, Diffuse Amyloidosis with Cardiac and Neurologic Involvement. Human Genetics, 89, 353-356. https://doi.org/10.1007/bf00220559 |
| [11] | Kon, T., Misumi, Y., Nishijima, H., Honda, M., Suzuki, C., Baba, M., et al. (2015) Effects of Liver Transplantation and Tafamidis in Hereditary Transthyretin Amyloidosis Caused by Transthyretin Leu55pro Mutation: A Case Report. Amyloid, 22, 203-204. https://doi.org/10.3109/13506129.2015.1031373 |
| [12] | Xu, J., Yang, M., Pan, X., Yu, X., Xie, J., Ren, H., et al. (2017) Transthyretin-Related Hereditary Amyloidosis with Recurrent Vomiting and Renal Insufficiency as the Initial Presentation: A Case Report. Medicine, 96, e5737. https://doi.org/10.1097/md.0000000000005737 |
| [13] | Lee, Y.J., Oh, J., Hwang, S., Lee, E.J., Yang, D.H., Kim, Y., et al. (2019) Extremely Early Onset Transthyretin Familial Amyloid Polyneuropathy with a Leu55pro Mutation: A Pediatric Case Report and Literature Review. Neuropediatrics, 50, 322-326. https://doi.org/10.1055/s-0039-1693145 |
| [14] | Castro-Rodrigues, A.F., Gales, L., Saraiva, M.J. and Damas, A.M. (2011) Structural Insights into a Zinc-Dependent Pathway Leading to Leu55pro Transthyretin Amyloid Fibrils. Acta Crystallographica Section D Biological Crystallography, 67, 1035-1044. https://doi.org/10.1107/s090744491104491x |
| [15] | Manolis, A.S., Manolis, A.A., Manolis, T.A. and Melita, H. (2019) Cardiac Amyloidosis: An Underdiagnosed/Underappreciated Disease. European Journal of Internal Medicine, 67, 1-13. https://doi.org/10.1016/j.ejim.2019.07.022 |
| [16] | Dohrn, M.F., Röcken, C., Bleecker, J.L., Martin, J., Vorgerd, M., Bergh, P.Y., et al. (2013) Diagnostic Hallmarks and Pitfalls in Late-Onset Progressive Transthyretin-Related Amyloid-Neuropathy. Journal of Neurology, 260, 3093-3108. https://doi.org/10.1007/s00415-013-7124-7 |
| [17] | Wixner, J., Mundayat, R., Karayal, O.N., Anan, I., Karling, P. and Suhr, O.B. (2014) THAOS: Gastrointestinal Manifestations of Transthyretin Amyloidosis-Common Complications of a Rare Disease. Orphanet Journal of Rare Diseases, 9, Article No. 61. https://doi.org/10.1186/1750-1172-9-61 |
| [18] | Aimo, A., Merlo, M., Porcari, A., Georgiopoulos, G., Pagura, L., Vergaro, G., et al. (2022) Redefining the Epidemiology of Cardiac Amyloidosis. A Systematic Review and Meta‐Analysis of Screening Studies. European Journal of Heart Failure, 24, 2342-2351. https://doi.org/10.1002/ejhf.2532 |
| [19] | Di Bella, G., Pizzino, F., Minutoli, F., Zito, C., Donato, R., Dattilo, G., et al. (2014) The Mosaic of the Cardiac Amyloidosis Diagnosis: Role of Imaging in Subtypes and Stages of the Disease. European Heart Journal—Cardiovascular Imaging, 15, 1307-1315. https://doi.org/10.1093/ehjci/jeu158 |
| [20] | Falk, R.H. and Quarta, C.C. (2015) Echocardiography in Cardiac Amyloidosis. Heart Failure Reviews, 20, 125-131. https://doi.org/10.1007/s10741-014-9466-3 |
| [21] | Martinez-Naharro, A., Treibel, T.A., Abdel-Gadir, A., Bulluck, H., Zumbo, G., Knight, D.S., et al. (2017) Magnetic Resonance in Transthyretin Cardiac Amyloidosis. Journal of the American College of Cardiology, 70, 466-477. https://doi.org/10.1016/j.jacc.2017.05.053 |
| [22] | Zhao, L., Tian, Z. and Fang, Q. (2016) Diagnostic Accuracy of Cardiovascular Magnetic Resonance for Patients with Suspected Cardiac Amyloidosis: A Systematic Review and Meta-Analysis. BMC Cardiovascular Disorders, 16, Article No. 129. https://doi.org/10.1186/s12872-016-0311-6 |
| [23] | Dungu, J.N., Valencia, O., Pinney, J.H., Gibbs, S.D.J., Rowczenio, D., Gilbertson, J.A., et al. (2014) CMR-Based Differentiation of AL and ATTR Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 7, 133-142. https://doi.org/10.1016/j.jcmg.2013.08.015 |
| [24] | Treglia, G., Glaudemans, A.W.J.M., Bertagna, F., Hazenberg, B.P.C., Erba, P.A., Giubbini, R., et al. (2018) Diagnostic Accuracy of Bone Scintigraphy in the Assessment of Cardiac Transthyretin-Related Amyloidosis: A Bivariate Meta-Analysis. European Journal of Nuclear Medicine and Molecular Imaging, 45, 1945-1955. https://doi.org/10.1007/s00259-018-4013-4 |
| [25] | Masri, A., Bukhari, S., Eisele, Y.S. and Soman, P. (2020) Molecular Imaging of Cardiac Amyloidosis. Journal of Nuclear Medicine, 61, 965-970. https://doi.org/10.2967/jnumed.120.245381 |
| [26] | Stats, M.A. and Stone, J.R. (2016) Varying Levels of Small Microcalcifications and Macrophages in ATTR and AL Cardiac Amyloidosis: Implications for Utilizing Nuclear Medicine Studies to Subtype Amyloidosis. Cardiovascular Pathology, 25, 413-417. https://doi.org/10.1016/j.carpath.2016.07.001 |
| [27] | Rapezzi, C., Quarta, C.C., Guidalotti, P.L., Pettinato, C., Fanti, S., Leone, O., et al. (2011) Role of 99mtc-Dpd Scintigraphy in Diagnosis and Prognosis of Hereditary Transthyretin-Related Cardiac Amyloidosis. JACC: Cardiovascular Imaging, 4, 659-670. https://doi.org/10.1016/j.jcmg.2011.03.016 |
| [28] | Glaudemans, A.W.J.M., van Rheenen, R.W.J., van den Berg, M.P., Noordzij, W., Koole, M., Blokzijl, H., et al. (2014) Bone Scintigraphy with 99mtechnetium-Hydroxymethylene Diphosphonate Allows Early Diagnosis of Cardiac Involvement in Patients with Transthyretin-Derived Systemic Amyloidosis. Amyloid, 21, 35-44. https://doi.org/10.3109/13506129.2013.871250 |
| [29] | Gillmore, J.D., Maurer, M.S., Falk, R.H., Merlini, G., Damy, T., Dispenzieri, A., et al. (2016) Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation, 133, 2404-2412. https://doi.org/10.1161/circulationaha.116.021612 |
| [30] | Castano, A., Haq, M., Narotsky, D.L., Goldsmith, J., Weinberg, R.L., Morgenstern, R., et al. (2016) Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients with ATTR Cardiac Amyloidosis. JAMA Cardiology, 1, 880-889. https://doi.org/10.1001/jamacardio.2016.2839 |
| [31] | Martini, N., Sinigiani, G., De Michieli, L., Mussinelli, R., Perazzolo Marra, M., Iliceto, S., et al. (2024) Electrocardiographic Features and Rhythm Disorders in Cardiac Amyloidosis. Trends in Cardiovascular Medicine, 34, 257-264. https://doi.org/10.1016/j.tcm.2023.02.006 |
| [32] | Brito, D., Albrecht, F.C., de Arenaza, D.P., Bart, N., Better, N., Carvajal-Juarez, I., et al. (2023) World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). Global Heart, 18, Article No. 59. https://doi.org/10.5334/gh.1262 |
